Jonathan Emberson
Impact in
- Infectious Diseases top 0.05%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Nephrology top 0.1%
- Chronic Kidney Disease and Diabetes
Papers in
- Nephrology 41
- Chronic Kidney Disease and Diabetes 35
-
- Cardiovascular Health and Risk Factors 17
- Blood Pressure and Hypertension Studies 9
- Co-authors
- Colin Baigent (45 shared papers)Kazem Rahimi (5 shared papers)John Philip Chalmers (2 shared papers)Simon George Anderson (1 shared paper)Dena Ettehad (1 shared paper)Connor A. Emdin (1 shared paper)Thomas Callender (1 shared paper)Anthony J. Rodgers (1 shared paper)
- Journals
- The Lancet (26 papers)European Heart Journal (19 papers)International Journal of Epidemiology (9 papers)American Journal of Kidney Diseases (8 papers)The Lancet Diabetes & Endocrinology (7 papers)
- Partner nations
- United KingdomUnited StatesMexico
In The Last Decade
Jonathan Emberson
219 papers receiving 58.9k citations
Jonathan Emberson's Hit Papers
Peers
Comparison fields: 5 of 195
- Infectious Diseases 11k
- Nephrology 3.8k
- Cardiology and Cardiovascular Medicine 6k
- Endocrinology, Diabetes and Metabolism 2.8k
- Surgery 7.1k
Countries citing papers authored by Jonathan Emberson
This map shows the geographic impact of Jonathan Emberson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Emberson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Emberson more than expected).
Fields of papers citing papers by Jonathan Emberson
This network shows the impact of papers produced by Jonathan Emberson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Emberson. The network helps show where Jonathan Emberson may publish in the future.
Co-authors
The 25 scholars most cited alongside Jonathan Emberson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 240 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | RoB 2: a revised tool for assessing risk of bias in randomised trials Hit paper breakdown → | 2019 | 23321 |
| 2 | Dexamethasone in Hospitalized Patients with Covid-19 Hit paper breakdown → | 2020 | 8764 |
| 3 | Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis Hit paper breakdown → | 2015 | 2794 |
| 4 | Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials Hit paper breakdown → | 2014 | 2102 |
| 5 | The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Hit paper breakdown → | 2011 | 1952 |
| 6 | Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 Hit paper breakdown → | 2020 | 1757 |
| 7 | Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 1531 |
| 8 | Interpretation of the evidence for the efficacy and safety of statin therapy Hit paper breakdown → | 2016 | 1457 |
| 9 | Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials Hit paper breakdown → | 2006 | 1166 |
| 10 | Comparison of Risk Prediction Using the CKD-EPI Equation and the MDRD Study Equation for Estimated Glomerular Filtration Rate Hit paper breakdown → | 2012 | 838 |
| 11 | Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials Hit paper breakdown → | 2022 | 760 |
| 12 | Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials Hit paper breakdown → | 2019 | 607 |
| 13 | Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study Hit paper breakdown → | 2019 | 585 |
| 14 | 2002 | 568 | |
| 15 | 2020 | 526 | |
| 16 | COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England Hit paper breakdown → | 2020 | 520 |
| 17 | 2003 | 425 | |
| 18 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 19 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 20 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
About Jonathan Emberson
Jonathan Emberson is a scholar working on Nephrology, Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Surgery and Infectious Diseases, having authored 240 papers that have together received 61.1k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (37 papers), Chronic Kidney Disease and Diabetes (35 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (20 papers), Genetic Associations and Epidemiology (19 papers), COVID-19 Clinical Research Studies (18 papers), Cardiovascular Health and Risk Factors (17 papers), Smoking Behavior and Cessation (11 papers) and Blood Pressure and Hypertension Studies (9 papers). The work is most often cited by research in Infectious Diseases (11k citations), Nephrology (3.8k citations), Cardiology and Cardiovascular Medicine (6k citations), Endocrinology, Diabetes and Metabolism (2.8k citations) and Surgery (7.1k citations). Jonathan Emberson has collaborated with scholars based in United Kingdom, United States and Mexico. Frequent co-authors include Colin Baigent, Kazem Rahimi, John Philip Chalmers, Simon George Anderson, Dena Ettehad, Connor A. Emdin, Thomas Callender, Anthony J. Rodgers, Amit Kiran and Peter H. Whincup. Their work appears in journals such as The Lancet, European Heart Journal, International Journal of Epidemiology, American Journal of Kidney Diseases and The Lancet Diabetes & Endocrinology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.